PMC:7105881 / 18404-19167 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"655","span":{"begin":31,"end":36},"obj":"Species"},{"id":"656","span":{"begin":37,"end":41},"obj":"Species"},{"id":"657","span":{"begin":53,"end":62},"obj":"Species"},{"id":"658","span":{"begin":64,"end":73},"obj":"Species"},{"id":"659","span":{"begin":75,"end":84},"obj":"Species"},{"id":"660","span":{"begin":90,"end":99},"obj":"Species"},{"id":"661","span":{"begin":140,"end":146},"obj":"Species"},{"id":"662","span":{"begin":148,"end":156},"obj":"Species"},{"id":"663","span":{"begin":158,"end":166},"obj":"Species"},{"id":"664","span":{"begin":172,"end":180},"obj":"Species"},{"id":"665","span":{"begin":209,"end":214},"obj":"Species"},{"id":"666","span":{"begin":215,"end":219},"obj":"Species"},{"id":"667","span":{"begin":323,"end":332},"obj":"Species"},{"id":"668","span":{"begin":398,"end":406},"obj":"Species"},{"id":"669","span":{"begin":459,"end":463},"obj":"Species"},{"id":"670","span":{"begin":473,"end":478},"obj":"Species"},{"id":"671","span":{"begin":613,"end":619},"obj":"Species"},{"id":"672","span":{"begin":648,"end":657},"obj":"Species"},{"id":"673","span":{"begin":741,"end":749},"obj":"Species"},{"id":"674","span":{"begin":754,"end":762},"obj":"Species"},{"id":"675","span":{"begin":337,"end":356},"obj":"Disease"},{"id":"676","span":{"begin":479,"end":489},"obj":"Disease"},{"id":"677","span":{"begin":599,"end":609},"obj":"Disease"}],"attributes":[{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"Tax:9606"},{"id":"A656","pred":"tao:has_database_id","subj":"656","obj":"Tax:11118"},{"id":"A657","pred":"tao:has_database_id","subj":"657","obj":"Tax:11137"},{"id":"A658","pred":"tao:has_database_id","subj":"658","obj":"Tax:277944"},{"id":"A659","pred":"tao:has_database_id","subj":"659","obj":"Tax:31631"},{"id":"A660","pred":"tao:has_database_id","subj":"660","obj":"Tax:290028"},{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"Tax:9606"},{"id":"A662","pred":"tao:has_database_id","subj":"662","obj":"Tax:694009"},{"id":"A663","pred":"tao:has_database_id","subj":"663","obj":"Tax:1335626"},{"id":"A664","pred":"tao:has_database_id","subj":"664","obj":"Tax:2697049"},{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"Tax:9606"},{"id":"A666","pred":"tao:has_database_id","subj":"666","obj":"Tax:11118"},{"id":"A667","pred":"tao:has_database_id","subj":"667","obj":"Tax:2697049"},{"id":"A668","pred":"tao:has_database_id","subj":"668","obj":"Tax:694009"},{"id":"A669","pred":"tao:has_database_id","subj":"669","obj":"Tax:11118"},{"id":"A670","pred":"tao:has_database_id","subj":"670","obj":"Tax:9606"},{"id":"A671","pred":"tao:has_database_id","subj":"671","obj":"Tax:9606"},{"id":"A672","pred":"tao:has_database_id","subj":"672","obj":"Tax:2697049"},{"id":"A673","pred":"tao:has_database_id","subj":"673","obj":"Tax:694009"},{"id":"A674","pred":"tao:has_database_id","subj":"674","obj":"Tax:1335626"},{"id":"A675","pred":"tao:has_database_id","subj":"675","obj":"MESH:D018352"},{"id":"A676","pred":"tao:has_database_id","subj":"676","obj":"MESH:D007239"},{"id":"A677","pred":"tao:has_database_id","subj":"677","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Unlike the four low pathogenic human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause mild to no pathogenesis in humans, SARS-CoV, MERS-CoV, and 2019-CoV are three highly pathogenic human CoVs (Channappanavar and Perlman, 2017; Cui et al., 2019; Zhu et al., 2020). With the increasing numbers of 2019-nCoV and MERS-CoV infections and continuous threat of re-emergence of SARS-CoV, as well as the potential of SARS- and MERS-related CoVs to cause human infections, it is critical to develop vaccines with strong efficacy and safety targeting these viruses to prevent their infections in humans. Since the vaccines against 2019-nCoV have not been available, the rest of the review will focus on the vaccines against SARS-CoV and MERS-CoV."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T68","span":{"begin":148,"end":156},"obj":"Disease"},{"id":"T69","span":{"begin":346,"end":356},"obj":"Disease"},{"id":"T70","span":{"begin":398,"end":406},"obj":"Disease"},{"id":"T71","span":{"begin":436,"end":440},"obj":"Disease"},{"id":"T72","span":{"begin":479,"end":489},"obj":"Disease"},{"id":"T73","span":{"begin":599,"end":612},"obj":"Disease"},{"id":"T74","span":{"begin":741,"end":749},"obj":"Disease"}],"attributes":[{"id":"A68","pred":"mondo_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A69","pred":"mondo_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A70","pred":"mondo_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A71","pred":"mondo_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A72","pred":"mondo_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A73","pred":"mondo_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Unlike the four low pathogenic human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause mild to no pathogenesis in humans, SARS-CoV, MERS-CoV, and 2019-CoV are three highly pathogenic human CoVs (Channappanavar and Perlman, 2017; Cui et al., 2019; Zhu et al., 2020). With the increasing numbers of 2019-nCoV and MERS-CoV infections and continuous threat of re-emergence of SARS-CoV, as well as the potential of SARS- and MERS-related CoVs to cause human infections, it is critical to develop vaccines with strong efficacy and safety targeting these viruses to prevent their infections in humans. Since the vaccines against 2019-nCoV have not been available, the rest of the review will focus on the vaccines against SARS-CoV and MERS-CoV."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T213","span":{"begin":31,"end":36},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T214","span":{"begin":140,"end":146},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T215","span":{"begin":209,"end":214},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T216","span":{"begin":473,"end":478},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T217","span":{"begin":574,"end":581},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T218","span":{"begin":613,"end":619},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T219","span":{"begin":711,"end":716},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"Unlike the four low pathogenic human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause mild to no pathogenesis in humans, SARS-CoV, MERS-CoV, and 2019-CoV are three highly pathogenic human CoVs (Channappanavar and Perlman, 2017; Cui et al., 2019; Zhu et al., 2020). With the increasing numbers of 2019-nCoV and MERS-CoV infections and continuous threat of re-emergence of SARS-CoV, as well as the potential of SARS- and MERS-related CoVs to cause human infections, it is critical to develop vaccines with strong efficacy and safety targeting these viruses to prevent their infections in humans. Since the vaccines against 2019-nCoV have not been available, the rest of the review will focus on the vaccines against SARS-CoV and MERS-CoV."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T20","span":{"begin":124,"end":136},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"Unlike the four low pathogenic human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause mild to no pathogenesis in humans, SARS-CoV, MERS-CoV, and 2019-CoV are three highly pathogenic human CoVs (Channappanavar and Perlman, 2017; Cui et al., 2019; Zhu et al., 2020). With the increasing numbers of 2019-nCoV and MERS-CoV infections and continuous threat of re-emergence of SARS-CoV, as well as the potential of SARS- and MERS-related CoVs to cause human infections, it is critical to develop vaccines with strong efficacy and safety targeting these viruses to prevent their infections in humans. Since the vaccines against 2019-nCoV have not been available, the rest of the review will focus on the vaccines against SARS-CoV and MERS-CoV."}

{"project":"2_test","denotations":[{"id":"32265848-28466096-36511071","span":{"begin":249,"end":253},"obj":"28466096"},{"id":"32265848-30531947-36511072","span":{"begin":267,"end":271},"obj":"30531947"}],"text":"Unlike the four low pathogenic human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause mild to no pathogenesis in humans, SARS-CoV, MERS-CoV, and 2019-CoV are three highly pathogenic human CoVs (Channappanavar and Perlman, 2017; Cui et al., 2019; Zhu et al., 2020). With the increasing numbers of 2019-nCoV and MERS-CoV infections and continuous threat of re-emergence of SARS-CoV, as well as the potential of SARS- and MERS-related CoVs to cause human infections, it is critical to develop vaccines with strong efficacy and safety targeting these viruses to prevent their infections in humans. Since the vaccines against 2019-nCoV have not been available, the rest of the review will focus on the vaccines against SARS-CoV and MERS-CoV."}

{"project":"LitCovid-sentences","denotations":[{"id":"T117","span":{"begin":0,"end":291},"obj":"Sentence"},{"id":"T118","span":{"begin":292,"end":620},"obj":"Sentence"},{"id":"T119","span":{"begin":621,"end":763},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Unlike the four low pathogenic human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause mild to no pathogenesis in humans, SARS-CoV, MERS-CoV, and 2019-CoV are three highly pathogenic human CoVs (Channappanavar and Perlman, 2017; Cui et al., 2019; Zhu et al., 2020). With the increasing numbers of 2019-nCoV and MERS-CoV infections and continuous threat of re-emergence of SARS-CoV, as well as the potential of SARS- and MERS-related CoVs to cause human infections, it is critical to develop vaccines with strong efficacy and safety targeting these viruses to prevent their infections in humans. Since the vaccines against 2019-nCoV have not been available, the rest of the review will focus on the vaccines against SARS-CoV and MERS-CoV."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T357","span":{"begin":31,"end":36},"obj":"SP_6;NCBITaxon:9606"},{"id":"T358","span":{"begin":140,"end":146},"obj":"NCBITaxon:9606"},{"id":"T359","span":{"begin":148,"end":156},"obj":"SP_10"},{"id":"T360","span":{"begin":158,"end":166},"obj":"SP_9"},{"id":"T361","span":{"begin":209,"end":214},"obj":"SP_6;NCBITaxon:9606"},{"id":"T362","span":{"begin":323,"end":332},"obj":"SP_7"},{"id":"T363","span":{"begin":337,"end":345},"obj":"SP_9"},{"id":"T364","span":{"begin":398,"end":406},"obj":"SP_10"},{"id":"T365","span":{"begin":436,"end":440},"obj":"SP_10"},{"id":"T366","span":{"begin":446,"end":450},"obj":"SP_9"},{"id":"T367","span":{"begin":473,"end":478},"obj":"SP_6;NCBITaxon:9606"},{"id":"T368","span":{"begin":574,"end":581},"obj":"NCBITaxon:10239"},{"id":"T369","span":{"begin":613,"end":619},"obj":"NCBITaxon:9606"},{"id":"T370","span":{"begin":648,"end":657},"obj":"SP_7"},{"id":"T371","span":{"begin":741,"end":749},"obj":"SP_10"},{"id":"T372","span":{"begin":754,"end":762},"obj":"SP_9"},{"id":"T61524","span":{"begin":31,"end":36},"obj":"SP_6;NCBITaxon:9606"},{"id":"T25405","span":{"begin":140,"end":146},"obj":"NCBITaxon:9606"},{"id":"T83538","span":{"begin":148,"end":156},"obj":"SP_10"},{"id":"T16158","span":{"begin":158,"end":166},"obj":"SP_9"},{"id":"T91311","span":{"begin":209,"end":214},"obj":"SP_6;NCBITaxon:9606"},{"id":"T35144","span":{"begin":323,"end":332},"obj":"SP_7"},{"id":"T65355","span":{"begin":337,"end":345},"obj":"SP_9"},{"id":"T92791","span":{"begin":398,"end":406},"obj":"SP_10"},{"id":"T26724","span":{"begin":436,"end":440},"obj":"SP_10"},{"id":"T76725","span":{"begin":446,"end":450},"obj":"SP_9"},{"id":"T98869","span":{"begin":473,"end":478},"obj":"SP_6;NCBITaxon:9606"},{"id":"T33066","span":{"begin":574,"end":581},"obj":"NCBITaxon:10239"},{"id":"T63813","span":{"begin":613,"end":619},"obj":"NCBITaxon:9606"},{"id":"T85793","span":{"begin":648,"end":657},"obj":"SP_7"},{"id":"T86382","span":{"begin":741,"end":749},"obj":"SP_10"},{"id":"T30191","span":{"begin":754,"end":762},"obj":"SP_9"}],"text":"Unlike the four low pathogenic human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause mild to no pathogenesis in humans, SARS-CoV, MERS-CoV, and 2019-CoV are three highly pathogenic human CoVs (Channappanavar and Perlman, 2017; Cui et al., 2019; Zhu et al., 2020). With the increasing numbers of 2019-nCoV and MERS-CoV infections and continuous threat of re-emergence of SARS-CoV, as well as the potential of SARS- and MERS-related CoVs to cause human infections, it is critical to develop vaccines with strong efficacy and safety targeting these viruses to prevent their infections in humans. Since the vaccines against 2019-nCoV have not been available, the rest of the review will focus on the vaccines against SARS-CoV and MERS-CoV."}